Pfizer Inc. (NYSE: PFE): Corporate Profile & Financials
Source: Pfizer Inc. Form 10-K 2025
Quick Facts / Company Snapshot
| Metric / Attribute | Disclosed Detail / Data Point |
|---|---|
| Company Name | Pfizer Inc. |
| Stock Exchange & Ticker Symbol | New York Stock Exchange (NYSE: PFE) |
| Corporate Headquarters | 66 Hudson Boulevard East, New York, New York 10001-2192 |
| Telephone Number | (212) 733-2323 |
| Jurisdiction of Incorporation | Delaware, United States |
| I.R.S. Employer Identification Number | 13-5315170 |
| Commission File Number | 1-3619 |
| Fiscal Year Ended | December 31, 2025 |
| Common Stock Par Value | $0.05 par value per share |
| Authorized Common Stock | 12,000,000,000 shares |
| Shares Outstanding (as of February 19, 2026) | 5,686,267,431 shares of common stock |
| Commercial Operating Segments | Biopharma, Pfizer CentreOne (PC1), and Pfizer Ignite |
| Sole Reportable Segment | Biopharma |
| Independent Registered Public Accounting Firm | KPMG LLP (New York, NY, Auditor Firm ID: 185) |
| Chairman & Chief Executive Officer | Albert Bourla |
| Chief Financial Officer | David M. Denton |
| Chief Accounting Officer & Controller | Jennifer B. Damico |
| Corporate Purpose | Breakthroughs that change patients’ lives |
| Blockbuster Product Count (>$1B in 2025 Revenue) | 12 products |
| Major Production Facility Profiled | Rocky Mount, North Carolina (injectable manufacturing facility) |
🏢 The Corporate Identity: Who They Are & Where They Came From
The Big Picture
Pfizer Inc. is a research-based, global biopharmaceutical enterprise dedicated to discovering, developing, manufacturing, marketing, selling, and distributing innovative medicines and vaccines worldwide. The organization leverages cutting-edge scientific expertise and vast global resources to advance medical solutions that extend and significantly enhance human lives.
The company operates primarily through the commercialization of human therapeutics across hospital, retail, and clinical settings. Commercial delivery is organized to address critical unmet medical needs, backed by enterprise-scale R&D operations and specialized commercial divisions that interface directly with healthcare providers, patients, regulatory bodies, and public health payors.
In fulfilling its stated purpose—Breakthroughs that change patients’ lives—Pfizer aligns capital deployment, cost structures, and research priorities toward sustaining long-term value creation. Commercial revenue generation is supplemented by contract manufacturing and drug development partnerships with external biotech innovators.
The Journey: History & Evolution
The enterprise has continually evolved through internal research and substantial strategic combinations, reorganizations, and asset realignments across several decades. Corporate actions disclosed in the regulatory filing highlight key transactions that have shaped the company’s operating scale and technological breadth:
- Warner-Lambert Combination (2000): Acquired full ownership of legacy portfolios, including inherited product liabilities and industrial operations such as American Optical Corporation (owned between 1967 and 1982).
- Pharmacia Merger (2003): Integrated Pharmacia & Upjohn Company LLC, which had previously merged with Former Monsanto Company in 2000 prior to spinning off New Monsanto in 2002 and Solutia Inc. in 1997.
- Wyeth Acquisition (2009): Added global vaccine infrastructure, the Prevnar franchise, and assumed responsibility for designated environmental remediation sites, including the Bound Brook, New Jersey facility.
- Hospira Integration (September 2015): Expanded generic sterile injectable hospital operations and established critical injectable manufacturing infrastructure.
- Upjohn Business Spin-Off (2020): Separated Pfizer’s legacy off-patent established medicine business to merge with Mylan, creating Viatris Inc. and leaving Pfizer as a focused, innovative biopharma enterprise.
- Seagen Inc. Acquisition (December 14, 2023): Acquired the commercial-stage biotechnology leader for $229 per share in cash, representing a total consideration of $44.2 billion ($43.4 billion net of cash acquired) to capture premier antibody-drug conjugate (ADC) oncology assets.
- Haleon Disinvestment (2024–2025): Monetized the legacy consumer healthcare joint venture with GlaxoSmithKline (GSK), completing a complete equity exit in the first quarter of 2025 for $6.3 billion in final net proceeds.
- Metsera Inc. Acquisition (November 13, 2025): Closed the purchase of the clinical-stage obesity and cardiometabolic company for $65.60 per share in cash plus milestone-based contingent value rights to rebuild Pfizer’s metabolic pipeline.
The Corporate Umbrella
Pfizer Inc. serves as the ultimate parent holding entity, operating through direct and indirect operating subsidiaries worldwide. Key specialized finance subsidiaries support the corporate capital structure, including:
- Pfizer Investment Enterprises Pte. Ltd. (PIE): A wholly-owned Singapore finance vehicle established in May 2023 to issue $31 billion in senior unsecured notes to finance the Seagen acquisition, fully and unconditionally guaranteed by Pfizer Inc.
- Pfizer Netherlands International Finance B.V. (PNIF): A wholly-owned Dutch financing subsidiary established to issue multi-currency European notes (including €3.3 billion issued in May 2025), fully and unconditionally guaranteed by Pfizer Inc.
⚙️ The Business Engine: What They Do & Where They Operate
The Core Divisions
During the fiscal year ended December 31, 2025, Pfizer managed its commercial operations through three operating segments, each led by an individual manager: Biopharma, Pfizer CentreOne (PC1), and Pfizer Ignite. Biopharma represents the company’s sole reportable segment under GAAP criteria.
Effective January 1, 2025, commercial operations inside the Biopharma segment were reorganized to combine former global Oncology commercial units into the Pfizer U.S. Commercial Division and the Pfizer International Commercial Division, while R&D was consolidated into a unified enterprise organization. At the beginning of 2026, Pfizer implemented an additional commercial reorganization, shifting off-patent branded and generic sterile injectables and biosimilars into a new Global Hospital and Biosimilars organization within the Biopharma segment. In 2025, the company made the decision to wind down Pfizer Ignite.
| Segment | Operational Scope & Core Activities | FY 2025 Revenue ($M) | % Share of Total *(Calculated by FirmsWorld)* | FY 2024 Revenue ($M) | FY 2023 Revenue ($M) | FY 2025 Segment Earnings ($M) | Depreciation & Amortization ($M) |
|---|---|---|---|---|---|---|---|
| Biopharma | Discovery, development, manufacture, marketing, sale, and distribution of human biopharmaceutical products globally across Primary Care, Specialty Care, and Oncology. | $61,199 | 97.79% | $62,400 | $58,237 | $29,342 | $1,379 |
| Pfizer CentreOne (PC1) | Contract development and manufacturing organization (CDMO) and leading global supplier of specialty active pharmaceutical ingredients (APIs). | $1,338 | 2.14% | $1,146 | $1,272 | Included in Other | Included in Other |
| Pfizer Ignite | Strategic guidance and end-to-end R&D services provider for innovative external biotech companies (currently winding down). | $41 | 0.07% | $82 | $44 | Included in Other | Included in Other |
| Other Business Activities | Unallocated corporate enabling functions, PC1/Ignite earnings, Haleon equity share, corporate real estate, and portfolio transactions. | $1,380 | N/A | $1,228 | $1,316 | $(8,199) | $305 |
The Global Product Catalog
The company maintains a broad portfolio spanning vaccines, internal medicine, inflammation and immunology, rare diseases, anti-infectives, and targeted oncology therapies. In 2025, Pfizer recorded twelve medicines and vaccines that each generated more than $1 billion in global revenue.
The total contribution of products exceeding $1 billion in annual revenue accounted for 65% of Total revenues in 2025, compared to 66% across eleven products in 2024 and 64% across nine products in 2023.
| Product / Family | Therapeutic Indication / Pharmacologic Class | FY 2025 Global Revenue ($M) | % Share of FY 2025 Revenue *(Calculated by FirmsWorld)* | FY 2024 Global Revenue ($M) | FY 2023 Global Revenue ($M) | Operational Growth % (2025 v. 2024) |
|---|---|---|---|---|---|---|
| Eliquis | Nonvalvular atrial fibrillation, DVT, pulmonary embolism | $7,961 | 12.72% | $7,366 | $6,747 | +7% |
| Prevnar family | Pneumococcal pneumonia, invasive disease, and otitis media | $6,494 | 10.38% | $6,411 | $6,501 | +1% |
| Vyndaqel family | ATTR cardiomyopathy (ATTR-CM) and polyneuropathy | $6,380 | 10.20% | $5,451 | $3,321 | +16% |
| Comirnaty | Active immunization against COVID-19 | $4,367 | 6.98% | $5,353 | $11,220 | -20% |
| Ibrance | HR-positive / HER2-negative metastatic breast cancer | $4,122 | 6.59% | $4,367 | $4,753 | -6% |
| Paxlovid | Oral antiviral for COVID-19 treatment in high-risk patients | $2,362 | 3.77% | $5,716 | $1,279 | -59% |
| Xtandi | Advanced prostate cancer (mCRPC, nmCRPC, mCSPC, nmCSPC) | $2,194 | 3.51% | $2,039 | $1,659 | +8% |
| Padcev | Locally advanced or metastatic urothelial cancer | $1,940 | 3.10% | $1,588 | $53 | +22% |
| Nurtec ODT/Vydura | Acute treatment and prevention of episodic migraine | $1,424 | 2.28% | $1,263 | $928 | +13% |
| Xeljanz | Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis | $1,087 | 1.74% | $1,168 | $1,703 | -7% |
| Abrysvo | Respiratory syncytial virus (RSV) immunization | $1,033 | 1.65% | $755 | $890 | +36% |
| Lorbrena | ALK-positive metastatic non-small cell lung cancer | $1,023 | 1.63% | $731 | $539 | +40% |
| Adcetris | CD30-positive lymphomas including Hodgkin lymphoma | $907 | 1.45% | $1,089 | $56 | -17% |
| Braftovi/Mektovi | BRAF-mutant metastatic melanoma and mCRC | $716 | 1.14% | $607 | $477 | +18% |
| Inflectra | Autoimmune and inflammatory conditions (infliximab biosimilar) | $646 | 1.03% | $509 | $490 | +27% |
| Sulperazon | Bacterial infections (ex-U.S. and Canada) | $653 | 1.04% | $637 | $757 | +3% |
| Zavicefta | Hospital-acquired bacterial infections (ex-U.S./Canada) | $638 | 1.02% | $586 | $511 | +9% |
| Enbrel | Rheumatoid arthritis, psoriasis (ex-U.S. and Canada) | $627 | 1.00% | $690 | $830 | -9% |
| Bosulif | Chronic myelogenous leukemia (CML) | $611 | 0.98% | $645 | $645 | -5% |
| Oncology Biosimilars | Supportive and therapeutic oncology (Retacrit, Ruxience, etc.) | $1,301 | 2.08% | $1,037 | $1,407 | +25% |
The Names You Know
Beyond immediate brand awareness, intellectual property protections dictate the lifespan of Pfizer’s product franchises. Generic market entrants and regulatory patent challenges heavily influence top-line performance.
The company disclosed key operational developments across its major commercial brands and upcoming intellectual property expirations:
- Patent-Based Expiries: Pfizer projects that revenue reductions resulting from patent expiries will reach $1.5 billion in 2026, with the annual rate of loss expected to significantly accelerate from 2026 through 2030.
- Eliquis: Selected by CMS for the Inflation Reduction Act’s Medicare Drug Price Negotiation Program (MDPNP), with the government-mandated Maximum Fair Price taking effect on January 1, 2026. A formulation patent expiring in 2031 is currently being litigated in Delaware against generic challenger Azurity.
- Ibrance & Xtandi: Selected for the MDPNP with Maximum Fair Prices becoming effective in 2027. ANDA patent litigation for Xtandi is ongoing in the U.S. District Court for the District of New Jersey.
- Xeljanz: Selected for MDPNP pricing taking effect in 2028.
- Vyndaqel/Vyndamax: Defending crystalline form, composition of matter, and method of treatment patents in the U.S. District Court for the District of Delaware against multiple generic filers who submitted Abbreviated New Drug Applications (ANDAs).
- Oxbryta: Following voluntary worldwide market withdrawal of all lots in September 2024 due to an unfavorable benefit-to-risk profile showing an imbalance in vaso-occlusive crises and fatal events, the European Commission suspended its marketing authorization in October 2024. In October 2025, the EMA adopted a negative opinion recommending continued suspension.
Mapping the Global Reach
Pfizer sells products across dozens of countries, attributing revenues geographically based on the location of the end customer. The United States represents the single largest country market, generating over half of total consolidated revenue.
| Geographic Region / Country | FY 2025 Revenue ($M) | % Share of Total *(Calculated by FirmsWorld)* | FY 2024 Revenue ($M) | FY 2023 Revenue ($M) | Operational Growth % (2025 v. 2024) |
|---|---|---|---|---|---|
| United States | $37,078 | 59.25% | $38,691 | $28,145 | -4% |
| International Developed Markets | $16,188 | 25.87% | $16,057 | $20,910 | +1% |
| International Emerging Markets | $9,313 | 14.88% | $8,879 | $10,498 | +5% |
| Total International Markets | $25,501 | 40.75% | $24,936 | $31,408 | +2% |
| Worldwide Total | $62,579 | 100.00% | $63,627 | $59,553 | -2% |
Revenues exceeded $500 million in each of 12 individual foreign nations during 2025, compared to 11 nations in 2024 and 14 nations in 2023. China represented the largest international market in both 2025 and 2024, accounting for 5% and 4% of total worldwide revenues, respectively. In 2023, Japan was the largest non-U.S. market, generating 6% of total corporate revenues.
In the U.S. wholesale distributor channel, customer concentration remains pronounced. Three major distributors represent a significant portion of consolidated business:
- McKesson Inc.: Accounted for 25% of Total revenues in 2025, 23% in 2024, and 16% in 2023.
- Cencora, Inc.: Accounted for 16% of Total revenues in 2025, 17% in 2024, and 12% in 2023.
- Cardinal Health, Inc.: Accounted for 13% of Total revenues in 2025, 14% in 2024, and 10% in 2023.
- Wholesale Accounts Receivable Exposure: Collectively, these three distributors represented 40% and 34% of trade accounts receivable as of December 31, 2025 and 2024, respectively.
The Brick & Mortar Footprint
The company maintains a worldwide manufacturing, research, and distribution infrastructure. Property, plant, and equipment (PP&E) assets are carried at historical cost less accumulated depreciation.
| Asset Category | Depreciation Useful Life Range (Years) | As of Dec 31, 2025 ($M) | As of Dec 31, 2024 ($M) | Latest YoY (%) |
|---|---|---|---|---|
| Land | N/A | $299 | $291 | +2.75% |
| Buildings | 33 – 50 years | $9,744 | $9,036 | +7.84% |
| Machinery & Equipment | 8 – 20 years | $16,140 | $15,095 | +6.92% |
| Furniture, Fixtures & Other | 3 – 12.5 years | $5,714 | $5,516 | +3.59% |
| Construction in Progress | N/A | $4,805 | $4,937 | -2.67% |
| Gross Property, Plant & Equipment | — | $36,702 | $34,876 | +5.24% |
| Less: Accumulated Depreciation | — | $(17,386) | $(16,483) | +5.48% |
| Total Property, Plant & Equipment, Net | — | $19,317 | $18,393 | +5.02% |
Geographically, net PP&E is distributed as follows:
- United States: $9,680 million as of December 31, 2025 ($9,748 million in 2024).
- International Developed Markets: $8,180 million as of December 31, 2025 ($7,187 million in 2024).
- International Emerging Markets: $1,457 million as of December 31, 2025 ($1,458 million in 2024).
- Rocky Mount, North Carolina Facility: Serves as a vital production site responsible for nearly 25% of all Pfizer sterile injectables (including anesthesia, analgesia, and micronutrients). Having sustained tornado damage in July 2023, medicine supply from the facility has fully recovered.
📊 The Financial Health: The Global Numbers Simplified
Earnings, Expenses, & Take-Home Profits
The consolidated statements of operations reflect the full financial results across research, manufacturing, commercialization, and acquisition-related integration.
| Consolidated Statements of Operations Line Item ($M, except per share) | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Product revenues | $51,663 | $53,816 | $50,914 |
| Alliance revenues | $9,266 | $8,388 | $7,582 |
| Royalty revenues | $1,650 | $1,423 | $1,058 |
| Total revenues | $62,579 | $63,627 | $59,553 |
| Cost of sales | $16,067 | $17,851 | $24,954 |
| Selling, informational and administrative expenses | $13,794 | $14,730 | $14,771 |
| Research and development expenses | $10,437 | $10,822 | $10,679 |
| Acquired in-process research and development expenses | $1,613 | $108 | $194 |
| Amortization of intangible assets | $4,874 | $5,286 | $4,733 |
| Restructuring charges and certain acquisition-related costs | $1,550 | $2,419 | $2,943 |
| Other (income)/deductions—net | $6,724 | $4,388 | $222 |
| Income from continuing operations before provision/(benefit) for taxes | $7,520 | $8,023 | $1,058 |
| Provision/(benefit) for taxes on income | $(266) | $(28) | $(1,115) |
| Income from continuing operations | $7,787 | $8,051 | $2,172 |
| Discontinued operations—net of tax | $25 | $11 | $(15) |
| Net income before allocation to noncontrolling interests | $7,812 | $8,062 | $2,158 |
| Less: Net income attributable to noncontrolling interests | $41 | $31 | $39 |
| Net income attributable to Pfizer Inc. common shareholders | $7,771 | $8,031 | $2,119 |
| Earnings per common share—basic: | |||
| Continuing operations | $1.37 | $1.42 | $0.38 |
| Discontinued operations | $— | $— | $— |
| Net income attributable to Pfizer Inc. common shareholders—basic | $1.37 | $1.42 | $0.38 |
| Earnings per common share—diluted: | |||
| Continuing operations | $1.36 | $1.41 | $0.37 |
| Discontinued operations | $— | $— | $— |
| Net income attributable to Pfizer Inc. common shareholders—diluted | $1.36 | $1.41 | $0.37 |
| Weighted-average shares—basic | 5,683 | 5,664 | 5,643 |
| Weighted-average shares—diluted | 5,713 | 5,700 | 5,709 |
Gross revenues were adjusted by $36,374 million in product revenue deductions during 2025, compared to $33,888 million in 2024 and $30,048 million in 2023. These deductions consisted of:
- Chargebacks: $13,973 million in 2025 ($12,698 million in 2024).
- Sales Allowances: $7,288 million in 2025 ($6,444 million in 2024).
- Performance-Based Contract Rebates: $7,034 million in 2025 ($6,497 million in 2024).
- Medicare Rebates: $4,511 million in 2025 ($4,145 million in 2024).
- Medicaid & State Program Rebates: $1,803 million in 2025 ($2,252 million in 2024).
- Sales Returns & Cash Discounts: $1,766 million in 2025 ($1,852 million in 2024).
Assets, Debts, & Corporate Wealth
The consolidated balance sheets detail Pfizer’s capital base, outstanding commercial debt, and cumulative equity balances.
| Consolidated Balance Sheets Line Item ($M) | As of Dec 31, 2025 | As of Dec 31, 2024 | Latest YoY (%) |
|---|---|---|---|
| Assets: | – | ||
| Cash and cash equivalents | $1,142 | $1,043 | +9.49% |
| Short-term investments | $12,454 | $19,434 | -35.92% |
| Trade accounts receivable, net of allowance ($427 in 2025; $438 in 2024) | $11,874 | $11,463 | +3.59% |
| Inventories | $10,654 | $10,851 | -1.82% |
| Current tax assets | $3,967 | $3,314 | +19.70% |
| Other current assets | $2,808 | $4,253 | -33.98% |
| Total current assets | $42,898 | $50,358 | -14.81% |
| Long-term investments | $1,621 | $2,228 | -27.24% |
| Property, plant and equipment, net | $19,317 | $18,393 | +5.02% |
| Identifiable intangible assets, net | $53,731 | $55,411 | -3.03% |
| Goodwill | $71,264 | $68,527 | +3.99% |
| Noncurrent deferred tax assets and other noncurrent tax assets | $9,699 | $8,662 | +11.97% |
| Other noncurrent assets | $9,631 | $9,817 | -1.89% |
| Total assets | $208,160 | $213,396 | -2.45% |
| Liabilities: | – | ||
| Short-term borrowings, including current portion of long-term debt | $3,154 | $6,946 | -54.59% |
| Trade accounts payable | $5,240 | $5,633 | -6.98% |
| Dividends payable | $2,445 | $2,437 | +0.33% |
| Income taxes payable | $3,103 | $2,910 | +6.63% |
| Accrued compensation and related items | $3,610 | $3,838 | -5.94% |
| Deferred revenues | $784 | $1,511 | -48.11% |
| Other current liabilities | $18,648 | $19,720 | -5.44% |
| Total current liabilities | $36,984 | $42,995 | -13.98% |
| Long-term debt | $61,641 | $57,405 | +7.38% |
| Pension and postretirement benefit obligations | $2,041 | $2,115 | -3.50% |
| Noncurrent deferred tax liabilities | $2,401 | $2,122 | +13.15% |
| Other taxes payable | $3,591 | $6,112 | -41.25% |
| Other noncurrent liabilities | $14,725 | $14,150 | +4.06% |
| Total liabilities | $121,385 | $124,899 | -2.81% |
| Pfizer Inc. Shareholders’ Equity: | – | ||
| Common stock ($0.05 par value; 9,621 shares issued in 2025; 9,593 in 2024) | $481 | $480 | +0.21% |
| Additional paid-in capital | $94,469 | $93,603 | +0.93% |
| Treasury stock, at cost (3,935 shares in 2025; 3,926 shares in 2024) | $(115,015) | $(114,763) | +0.22% |
| Retained earnings | $114,610 | $116,725 | -1.81% |
| Accumulated other comprehensive loss | $(8,069) | $(7,842) | +2.89% |
| Total Pfizer Inc. shareholders’ equity | $86,476 | $88,203 | -1.96% |
| Equity attributable to noncontrolling interests | $299 | $294 | +1.70% |
| Total equity | $86,775 | $88,497 | -1.95% |
| Total liabilities and equity | $208,160 | $213,396 | -2.45% |
Cash Flow: Tracking the Money Movement
The consolidated cash flows illustrate how the company generates operating liquidity and directs capital into acquisitions, capital equipment, debt service, and shareholder dividends.
| Consolidated Statements of Cash Flows Line Item ($M) | FY 2025 | FY 2024 | FY 2023 | Latest YoY (%) |
|---|---|---|---|---|
| Operating Activities: | – | |||
| Net income before allocation to noncontrolling interests | $7,812 | $8,062 | $2,158 | -3.10% |
| Discontinued operations—net of tax | $25 | $11 | $(15) | +127.27% |
| Net income from continuing operations | $7,787 | $8,051 | $2,172 | -3.28% |
| Depreciation and amortization | $6,592 | $7,013 | $6,290 | -6.00% |
| Asset write-offs and impairments | $5,270 | $4,242 | $3,408 | +24.23% |
| Deferred taxes | $(2,133) | $(2,102) | $(3,442) | +1.47% |
| Share-based compensation expense | $799 | $877 | $525 | -8.89% |
| Benefit plan contributions in excess of expense/income | $(786) | $(12) | $(787) | +6450.00% |
| COVID-19 inventory write-offs and related charges | $— | $— | $6,199 | – |
| Other non-cash adjustments, net | $(470) | $(2,260) | $(3,492) | -79.20% |
| Trade accounts receivable (change) | $(263) | $(109) | $347 | +141.28% |
| Inventories (change) | $561 | $(854) | $(1,169) | N/M |
| Other assets (change) | $1,289 | $3,380 | $(663) | -61.86% |
| Trade accounts payable (change) | $(469) | $(1,023) | $(300) | -54.15% |
| Other liabilities (change) | $(3,667) | $(3,115) | $595 | +17.72% |
| Other tax accounts, net (change) | $(2,805) | $(1,345) | $(982) | +108.55% |
| Net cash provided by operating activities | $11,704 | $12,744 | $8,700 | -8.16% |
| Investing Activities: | – | |||
| Purchases of property, plant and equipment | $(2,629) | $(2,909) | $(3,907) | -9.63% |
| Purchases of short-term investments | $(14,356) | $(10,133) | $(30,974) | +41.68% |
| Proceeds from redemptions/sales of short-term investments | $17,959 | $4,128 | $39,264 | +335.05% |
| Net (purchases)/proceeds: short-term investments (<3 months) | $(2,675) | $3,136 | $5,174 | N/M |
| Purchases of long-term investments | $(294) | $(180) | $(204) | +63.33% |
| Proceeds from redemptions/sales of long-term investments | $1,095 | $1,570 | $1,979 | -30.25% |
| Proceeds from sales of investment in Haleon | $6,311 | $7,040 | $— | -10.36% |
| Acquisitions of businesses, net of cash acquired | $(6,927) | $— | $(43,430) | – |
| Other investing activities, net | $165 | $2 | $(179) | +8150.00% |
| Net cash provided by/(used in) investing activities | $(1,351) | $2,652 | $(32,278) | N/M |
| Financing Activities: | – | |||
| Proceeds from short-term borrowings | $— | $8,907 | $4,525 | – |
| Payments on short-term borrowings | $(2,199) | $(11,226) | $(3) | -80.41% |
| Net (payments)/proceeds: short-term borrowings (<3 months) | $(796) | $(2,590) | $3,161 | -69.27% |
| Proceeds from issuance of long-term debt | $9,678 | $— | $30,831 | – |
| Payments on long-term debt | $(6,757) | $(2,250) | $(2,569) | +200.31% |
| Cash dividends paid | $(9,771) | $(9,512) | $(9,247) | +2.72% |
| Other financing activities, net | $(458) | $(469) | $(631) | -2.35% |
| Net cash provided by/(used in) financing activities | $(10,304) | $(17,140) | $26,066 | -39.88% |
| Effect of exchange-rate changes | $41 | $(66) | $(40) | N/M |
| Net increase/(decrease) in cash, cash equivalents & restricted cash | $91 | $(1,810) | $2,448 | N/M |
| Cash, cash equivalents & restricted cash, beginning of period | $1,107 | $2,917 | $468 | -62.05% |
| Cash, cash equivalents & restricted cash, end of period | $1,197 | $1,107 | $2,917 | +8.13% |
Funding the Future: R&D and Expansion Spending
Pfizer relies on disciplined capital expenditure planning alongside innovative co-funding arrangements with specialized life-science investment firms to de-risk clinical programs:
- 2026 PP&E Capital Guidance: Pfizer expects to spend approximately $2.5 billion on capital property, plant, and equipment purchases in 2026.
- Enforceable Contractual Commitments: As of December 31, 2025, Pfizer had $5.0 billion in total legally binding purchase obligations and expected milestone commitments ($1.6 billion payable within 12 months, and $3.4 billion due thereafter).
- TCJA Repatriation Tax Obligation: Under the Tax Cuts and Jobs Act (TCJA), the eighth and final installment of the foreign earnings Transition Tax liability, totaling $2.6 billion, is due on April 15, 2026 and is classified within current Income taxes payable.
- Abingworth R&D Funding Agreement: Executed in September 2025, providing up to $200 million between 2025 and 2027 to co-fund clinical development (offsetting 2025 R&D expense by $54 million). In return, Abingworth is eligible for up to $120 million in fixed approval milestones and up to $280 million in cumulative sales-based milestones, plus mid-single-digit royalties.
- Blackstone R&D Arrangements: In March 2025, Pfizer entered an agreement with Blackstone to receive up to $326 million through 2028 (offsetting 2025 R&D expense by $102 million), with Blackstone eligible for up to $277 million in approval milestones and up to $897 million in sales-based milestones. This follows an April 2023 agreement providing up to $550 million (which offset R&D expenses by $57 million in 2025, $135 million in 2024, and $175 million in 2023).
🗺️ The Corporate Family Tree: Structure & Investments
Subsidiaries, Associates, & Shared Ventures
The enterprise conducts global operations through operational joint collaborations and co-promotion partnerships:
- BioNTech SE: Collaborative partner for Comirnaty. Operating under a 50% gross profit-sharing structure; Pfizer recorded $911 million in remaining profit-share liabilities payable to BioNTech as of December 31, 2025 ($1.3 billion as of December 31, 2024).
- Bristol Myers Squibb (BMS): Strategic partner for Eliquis. Pfizer shares gross profits and records alliance revenues for co-promotion. Alliance revenues under collaborative agreements reached $9,266 million in 2025.
- Astellas Pharma Inc.: Joint development and commercialization partner for Padcev and Xtandi. Under the Padcev agreement, Astellas commercializes outside the Americas, while Pfizer retains Americas rights.
- Genmab A/S: Collaboration partner for Tivdak.
- Valneva SE: Strategic development partner advancing the VLA15 Lyme disease vaccine candidate.
- RemeGen Co., Ltd.: Collaboration partner co-developing disitamab vedotin.
Strategic Investments & Minority Stakes
Pfizer holds strategic minority equity positions in commercial businesses and emerging biotechnology innovators:
| Entity Name | Equity Ownership % | Nature of Relationship / Holding Classification | Country of Incorporation | FY 2025 Disclosed Cash Return / Carrying Value |
|---|---|---|---|---|
| ViiV Healthcare Limited | 11.7% | Specialized HIV medicine enterprise (GSK joint venture); equity method suspended since 2016 at $0 carrying basis. In January 2026, Pfizer agreed to sell this stake for $1.9 billion. | United Kingdom | $265 million in 2025 dividend income ($272 million in 2024; $265 million in 2023). |
| Haleon plc | 0.0% (Exited) | Publicly traded consumer health entity (former 32% stake reduced to 15% in 2024; sold remaining stake in Q1 2025 for $6.3B). | United Kingdom | $6,311 million in 2025 divestiture cash proceeds; $(144) million recognized net loss on sale. |
| 3SBio Inc. | Minority equity | Biopharmaceutical company partnering on bispecific antibody PF-08634404. Pfizer acquired an equity position alongside an in-licensing agreement. | China | $100 million direct equity purchase completed in July 2025. |
👥 Power & Control: Who Pulls the Strings?
The Brain Trust: Board of Directors & Executive Leadership
The company is governed by a Board of Directors alongside corporate executive officers responsible for strategic operations and financial disclosures:
- Albert Bourla, DVM, Ph.D.: Chairman and Chief Executive Officer (Principal Executive Officer).
- David M. Denton: Chief Financial Officer, Executive Vice President (Principal Financial Officer).
- Jennifer B. Damico: Senior Vice President and Controller (Principal Accounting Officer).
- Margaret M. Madden: Senior Vice President, Corporate Secretary, and Chief Governance Counsel.
- Douglas M. Lankler: Executive Officer and Attorney-in-Fact.
- Ronald E. Blaylock: Independent Director.
- Mortimer J. Buckley: Independent Director.
- Susan Desmond-Hellmann, M.D., M.P.H.: Independent Director.
- Joseph J. Echevarria: Independent Director.
- Scott Gottlieb, M.D.: Independent Director.
- Susan Hockfield, Ph.D.: Independent Director.
- Dan R. Littman, M.D., Ph.D.: Independent Director.
- Shantanu Narayen: Independent Director.
- Suzanne Nora Johnson: Independent Director.
- James Quincey: Independent Director.
- James C. Smith: Independent Director.
- Cyrus Taraporevala: Independent Director.
Who Owns the Stock?
As of February 19, 2026, Pfizer had 5,686,267,431 shares of common stock outstanding (all of one single class, $0.05 par value). The company’s authorized share capital encompasses 12,000,000,000 shares of common stock and 27,000,000 shares of preferred stock without par value (no preferred shares issued or outstanding).
Treasury stock held at cost totaled 3,935 million shares ($115,015 million) as of December 31, 2025, compared to 3,926 million shares ($114,763 million) as of December 31, 2024. Under the company’s publicly announced share-purchase program authorized by the Board of Directors, Pfizer had a remaining share-purchase authorization of $3.3 billion as of December 31, 2025, with zero open-market share repurchases executed during 2025.
🎯 The Strategic Outlook: Future Plans & Potential Pitfalls
Competitive Advantages & Economic Moats
Pfizer’s competitive positioning is anchored in several structural advantages disclosed in the report:
- Global Commercial Scale: Broad commercial and distribution reach enabled $62.6 billion in global revenue during 2025, with infrastructure capable of marketing therapies across both mature Western economies and high-growth emerging markets.
- Diversified Product Portfolio: Twelve separate medicines and vaccines generate over $1 billion annually, insulating corporate cash flows from single-asset dependencies.
- Proprietary ADC Leadership: The complete integration of Seagen provides industry-leading antibody-drug conjugate (ADC) technological capabilities, powering growth in therapies like Padcev (up 22% operationally in 2025).
- Balance Sheet & Liquidity Access: High-quality long-term investment-grade credit ratings (Moody’s: A2 / Stable; S&P: A / Stable) provide flexible debt access, supported by an undrawn $7.0 billion committed revolving credit facility expiring in October 2030.
What Could Go Wrong? Key Challenges & Business Risks
Management identifies substantial regulatory, commercial, and operational head-winds:
- Patent Cliff Acceleration: The enterprise anticipates an immediate $1.5 billion top-line hit in 2026 due to exclusivity expiries, with patent expiration losses accelerating markedly through 2030 across core franchises.
- U.S. Pricing and the Inflation Reduction Act: The IRA’s Medicare Part D Benefit Redesign negatively impacted 2025 revenue by approximately $1.0 billion by pushing catastrophic coverage thresholds earlier in the calendar year. Government-mandated Maximum Fair Prices took effect for Eliquis on January 1, 2026, with Ibrance and Xtandi following in 2027 and Xeljanz in 2028.
- Asset Impairment Vulnerability: The uncertain nature of clinical research resulted in $4,940 million in pre-tax intangible asset impairments in 2025, including $1.6 billion written off for disitamab vedotin, $820 million for Tukysa, and $820 million for osivelotor due to clinical and commercial changes.
- Patent and Product Litigation Exposure: ModernaTX continues to pursue global patent infringement damages regarding Comirnaty’s mRNA platform (with conflicting court rulings across the U.S., Germany, the Netherlands, and the U.K.). Separately, coordinated federal and state product liability proceedings continue for Zantac, Depo-Provera (meningioma claims transferred to a Florida MDL in February 2025), and Chantix.
- Executive Tariffs & Trade Exposure: The company is monitoring international trade actions, executive tariffs under Section 232, and the Supreme Court’s February 2026 ruling regarding the International Emergency Economic Powers Act (IEEPA). In September 2025, Pfizer entered a voluntary arrangement with the Trump Administration to provide discounted pricing to U.S. patients in exchange for a three-year grace period from Section 232 tariffs, conditioned upon further U.S. manufacturing investments.
The Next Chapter: Growth & Expansion Initiatives
To overcome loss-of-exclusivity headwinds and post-pandemic demand declines, Pfizer is executing an enterprise-wide transformation focused on four defined priorities for 2026:
- Maximize Value of Key Transactions: Fully capitalize on the commercial launches resulting from the Seagen and Metsera acquisitions. In obesity, Pfizer acquired Metsera’s clinical monthly injectable candidates MET-097i (GLP-1 receptor antagonist) and MET-233i (amylin analog combination), while adding YaoPharma’s small-molecule oral GLP-1 candidate YP05002 in December 2025.
- Deliver on Critical R&D Milestones: Advance 20 late-stage development programs, including combination therapies for Padcev and Tukysa, next-generation breast cancer oral selective estrogen receptor degrader vepdegestrant (partnered with Arvinas), and the VLA15 Lyme disease vaccine (partnered with Valneva).
- Enterprise Efficiency Programs:
- Realigning Our Cost Base Program: Targeting $5.7 billion in net cost savings through 2026 ($5.1 billion achieved through 2025, with $600 million remaining to be achieved by year-end 2026).
- Manufacturing Optimization Program: Phase 1 targets $1.5 billion in annual cost of goods sold reductions by 2027 ($600 million realized through year-end 2025).
- Acquisition Synergies: On track to capture $1.0 billion in annual Seagen synergies and $600 million in annual Metsera synergies by year-end 2026.
- Scale Artificial Intelligence Across the Organization: Deploying automation, predictive modeling, and enterprise digital solutions across commercial execution and R&D platforms to lower clinical trial durations and improve general operating efficiency.
The Verdict: Strategic Outlook & Conclusion
Pfizer stands at a critical strategic pivot. Having navigated sharp contractions in COVID-19 product revenues—which saw Comirnaty fall 20% and Paxlovid decline 59% operationally in 2025—the underlying non-COVID commercial portfolio demonstrated resilience, advancing 6% operationally.
With $1.5 billion in exclusivity expiries approaching in 2026 and government-mandated price cuts under the IRA entering enforcement, execution of the Seagen oncology pipeline, the Metsera cardiometabolic portfolio, and multi-billion-dollar cost reduction programs will serve as the primary determinants of the company’s ability to maintain earnings stability and achieve post-2028 operating expansion.
Official Site: https://www.pfizer.com